Race-based therapeutics
Race-based therapeutics
复制标题
DOI：
10.1007/s11906-008-0052-8
复制
发表时间：
2008-08-01
影响因子：
5.6
通讯作者：
Yancy, Clyde W.
中科院分区：
文献类型：
--
作者：
Yancy, Clyde W.
医学中的种族问题是有问题的。种族不是一个生理分组，一个特定种族的所有人不一定具有相同的临床表型或遗传基础。尽管有明确的信号表明，某些风险因素和疾病因种族而异，但将这些差异转化为基于种族的治疗方法一直很尴尬，并且对改变心血管疾病的自然史几乎没有作用，因为它会影响特殊人群。在各种特殊人群中，非洲裔美国人人群似乎具有最显著和最不利的心血管疾病变化以及药物反应性变化的令人担忧的信号。最近的指南声明现在已经承认某些治疗方案最适合患有心血管疾病的非洲裔美国人，特别是高血压和心力衰竭。随着越来越多的疾病和药物反应的生理标志物变得可用，医学中对种族指定的需求可能会减少，并且可以为所有患者优化治疗，而不考虑种族或民族。
The issue of race in medicine is problematic. Race is not a physiologic grouping, and all persons of a given race do not necessarily share the same clinical phenotype or genetic substrate. Despite clear signals that certain risk factors and diseases vary as a function of race, translating those differences into race-based therapeutics has been awkward and has done little to change the natural history of cardiovascular disease as it affects special populations. Among the varied special populations, the African American population appears to have the most significant and adverse variances for cardiovascular disease as well as worrisome signals that drug responsiveness varies. Recent guideline statements have now acknowledged certain treatment options that are most appropriate for African Americans with cardiovascular disease, especially hypertension and heart failure. As more physiologic markers of disease and drug responsiveness become available, the need for racial designations in medicine may lessen, and therapies can be optimized for all patients without regard to race or ethnicity.